Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

L9761

Sigma-Aldrich

[D-Trp6]-LH-RH

≥97% (HPLC), powder

Synonym(s):

[D-Trp6]-Luteinizing hormone releasing hormone

Sign Into View Organizational & Contract Pricing

Select a Size

1 MG
€113.00
5 MG
€312.00

€113.00

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
1 MG
€113.00
5 MG
€312.00

About This Item

Empirical Formula (Hill Notation):
C64H82N18O13
CAS Number:
57773-63-4
Molecular Weight:
1311.45
MDL number:
MFCD00167541
UNSPSC Code:
12352209
PubChem Substance ID:
329817674
NACRES:
NA.32

€113.00

Please contact Customer Service for Availability
Request a Bulk Order

Quality Level

200

Assay

≥97% (HPLC)

form

powder

UniProt accession no.

P01148
P30968

storage temp.

−20°C

SMILES string

CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6c[nH]cn6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O

InChI

1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1

InChI key

VXKHXGOKWPXYNA-PGBVPBMZSA-N

Gene Information

human ... GNRH1(2796) , GNRHR(2798)

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence

Glp-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2

Application

[D-Trp6]-LH-RH (luteinizing hormone releasing hormone) has been used to study whether the (M. – X) region in electron capture dissociation provides information on amino acid composition of polypeptides.[1] It is also used to study the effect of LH-RH on the production of progesterone (P), estradiol (E2) or human chorionic gonadotropin (hCG) by JEG-3 choriocarcinoma cells.[2]

Biochem/physiol Actions

Potent LH-RH agonist with enhanced biological activity due to its slower rate of degradation. Like [D-Lys6]-LH-RH, the D-Trp6 analog has been shown to be effective against cancers expressing the LH-RH receptor. However, unlike the D-Lys6 analog, it is generally used in the unconjugated form.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCH1269
BCCB4898
BCBX4005
BCBT0543
BCBQ4733V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Colette Meyer et al.
Endocrine-related cancer, 20(1), 123-136 (2012-12-04)
GNRH significantly inhibits proliferation of a proportion of cancer cell lines by activating GNRH receptor (GNRHR)-G protein signaling. Therefore, manipulation of GNRHR signaling may have an under-utilized role in treating certain breast and ovarian cancers. However, the precise signaling pathways
S Romagnoli et al.
Reproduction in domestic animals = Zuchthygiene, 47 Suppl 6, 389-392 (2013-01-04)
The purpose of this study was to define (i) the interval between treatment and sterility, and (ii) semen quality in male dogs administered a 4.7-mg deslorelin implant. Six healthy, adult dogs of various breeds and body weights were implanted with
Sandra Goericke-Pesch et al.
Theriogenology, 79(4), 640-646 (2012-12-26)
Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on
J W Kim et al.
Gynecologic oncology, 73(3), 368-371 (1999-06-15)
Gonadotropin-releasing hormone (GnRH) has been shown to have an inhibitory effect on the growth of several hormone-dependent human tumors. We have treated a human endometrial cancer cell line which expresses GnRH receptor with GnRH analog, D-Trp6-LHRH, in order to study
G Emons et al.
Cancer research, 53(22), 5439-5446 (1993-11-15)
Recently, specific binding sites for luteinizing hormone releasing hormone (LHRH) and its analogues have been demonstrated in biopsy samples of human epithelial ovarian cancer. Their biological significance remained obscure. In this study we ascertained whether such LHRH-binding sites are also
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service